Wall Street analysts forecast that Qiagen (QGEN Quick QuoteQGEN - Free Report) will report quarterly earnings of $0.50 per share in its upcoming release, pointing to a year-over-year increase of 6.4%. It is anticipated that revenues will amount to $464.04 million, exhibiting an increase of 1.1% compared to the year-ago quarter.

The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

Given this perspective, it's time to examine the average forecasts of specific Qiagen metrics that are routinely monitored and predicted by Wall Street analysts.

Analysts forecast 'Sales by Product Groups- Diagnostic solutions- QIAstat-Dx' to reach $30.15 million. The estimate suggests a change of +20.6% year over year.

The combined assessment of analysts suggests that 'Sales by Product Groups- Diagnostic solutions- QuantiFERON' will likely reach $111.16 million. The estimate indicates a year-over-year change of +10.1%.

The average prediction of analysts places 'Sales by Product Groups- Sample technologies' at $150.54 million. The estimate suggests a change of -2.9% year over year.

Based on the collective assessment of analysts, 'Sales by Product Groups- Diagnostic solutions' should arrive at $180.35 million. The estimate suggests a change of +6.1% year over year.

The consensus among analysts is that 'Sales by Product Groups- Diagnostic solutions- NeuMoDx' will reach $4.60 million. The estimate indicates a change of -48.9% from the prior-year quarter.

It is projected by analysts that the 'Sales by Product Groups- Genomics / NGS' will reach $54.60 million. The estimate indicates a change of -0.7% from the prior-year quarter.

Analysts' assessment points toward 'Sales by Product Groups- PCR / Nucleic acid amplification' reaching $67.64 million. The estimate suggests a change of -0.5% year over year.

The collective assessment of analysts points to an estimated 'Sales by Product Groups- Other' of $10.95 million. The estimate points to a change of -0.5% from the year-ago quarter.

Analysts expect 'Revenue- Molecular Diagnostics' to come in at $252.58 million. The estimate indicates a change of +3.5% from the prior-year quarter.

The consensus estimate for 'Revenue- Life Sciences' stands at $211.17 million. The estimate points to a change of -1.8% from the year-ago quarter.

According to the collective judgment of analysts, 'Sales by Product Groups- Diagnostic solutions- Other' should come in at $34.45 million. The estimate suggests a change of -1.6% year over year.

View all Key Company Metrics for Qiagen here>>>

Shares of Qiagen have demonstrated returns of +6.2% over the past month compared to the Zacks S&P 500 composite's +11.5% change. With a Zacks Rank #2 (Buy), QGEN is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>